$ADTX
Aditxt, Inc. Stock $adtx

$adtx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000121390024033466 Filed on April 16, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$44.28K	$81.30K	$645.2K
YoY Change	-79.96%	-56.2%	-30.9%
Cost Of Revenue	$23.13K	$285.9K	$756.8K
YoY Change	-87.54%	67.99%	-1.3%
Gross Profit	$21.14K	-$204.6K	-$111.7K
YoY Change	-40.01%	-1425.79%	-166.89%
Gross Profit Margin	47.75%	-251.62%	-17.31%
Selling, General & Admin	$4.444M	$3.443M	$18.88M
YoY Change	17.41%	-32.94%	920.65%
% of Gross Profit	21018.65%
Research & Development	$1.553M	$4.303M	$7.074M
YoY Change	220.39%	39.66%	-2.67%
% of Gross Profit	7347.27%
Depreciation & Amortization	$157.2K	$132.9K	$542.6K
YoY Change	43.03%	-16.42%	26.48%
% of Gross Profit	743.53%
Operating Expenses	$5.997M	$7.746M	$25.95M
YoY Change	40.46%	-5.71%	1.18%
Operating Profit	-$5.976M	-$7.951M	-$26.06M
YoY Change	41.13%	-3.04%	2.29%
Interest Expense	-$1.648M	-$3.079M	-$6.380M
YoY Change	13.84%	-18338.45%	186.25%
% of Operating Profit
Other Income/Expense, Net	-$1.648M		-$6.328M
YoY Change	13.84%		-391.64%
Pretax Income	-$7.624M	-$10.98M	-$32.39M
YoY Change	34.18%	34.15%	17.15%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.550M	-$11.12M	-$32.70M
YoY Change	32.87%	35.9%	18.27%
Net Earnings / Revenue	-17051.27%	-13678.87%	-5068.46%
Basic Earnings Per Share	-$4.19		-$108.20
Diluted Earnings Per Share	-$4.19	-$15.10	-$108.20
COMMON SHARES
Basic Shares Outstanding	1.665M shares	441.9K shares	302.4K shares
Diluted Shares Outstanding	1.802M shares		302.4K shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$91.22K	$97.10K	$97.10K
YoY Change	-4.93%	-96.49%	-96.49%
Cash & Equivalents	$91.22K	$97.10K
Short-Term Investments
Other Short-Term Assets	$443.3K	$217.4K	$217.4K
YoY Change	-32.21%	-56.25%	-56.25%
Inventory	$565.5K	$745.5K	$745.5K
Prepaid Expenses	$443.3K	$217.4K
Receivables	$406.6K	$408.3K	$408.3K
Other Receivables	$0.00	$5.445M	$5.445M
Total Short-Term Assets	$1.507M	$6.913M	$6.913M
YoY Change	-29.85%	45.73%	45.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.865M	$4.099M	$4.099M
YoY Change	-11.38%	76.75%	-25.2%
Goodwill
YoY Change
Intangibles	$7.778K	$9.444K
YoY Change		-91.17%
Long-Term Investments	$23.28M	$22.38M	$22.38M
YoY Change	8002.9%	6198.68%	6198.68%
Other Assets		$11.17M	$11.17M
YoY Change			22247.54%
Total Long-Term Assets	$26.87M	$37.67M	$37.67M
YoY Change	422.08%	528.63%	528.63%
TOTAL ASSETS
Total Short-Term Assets	$1.507M	$6.913M	$6.913M
Total Long-Term Assets	$26.87M	$37.67M	$37.67M
Total Assets	$28.37M	$44.58M	$44.58M
YoY Change	289.02%	315.25%	315.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.14M	$8.555M	$8.555M
YoY Change	143.41%	336.81%	336.81%
Accrued Expenses	$734.8K	$999.9K	$999.9K
YoY Change	-33.37%	-7.98%	-7.98%
Deferred Revenue
YoY Change
Short-Term Debt	$6.413M	$16.03M	$16.03M
YoY Change	119.93%
Long-Term Debt Due	$147.8K	$147.8K	$147.8K
YoY Change	0.0%	-63.94%	-63.94%
Total Short-Term Liabilities	$20.57M	$25.89M	$25.89M
YoY Change	111.06%	610.53%	610.53%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.465M	$2.642M	$2.642M
YoY Change	3.23%	40.13%	40.13%
Total Long-Term Liabilities	$1.465M	$2.642M	$2.642M
YoY Change	3.23%	40.13%	40.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.57M	$25.89M	$25.89M
Total Long-Term Liabilities	$1.465M	$2.642M	$2.642M
Total Liabilities	$22.03M	$28.52M	$28.52M
YoY Change	97.35%	415.87%	415.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$150.0M	-$127.7M
YoY Change	40.59%	34.41%
Common Stock	$1.993K	$1.319K
YoY Change	-70.54%	-69.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$201.6K	$201.6K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$6.566M	$16.06M	$16.06M
YoY Change
Total Liabilities & Shareholders Equity	$28.37M	$44.58M	$44.58M
YoY Change	289.02%	315.25%	315.25%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$7.550M	-$11.12M	-$32.70M
YoY Change	32.87%	35.9%	18.27%
Depreciation, Depletion And Amortization	$157.2K	$132.9K	$542.6K
YoY Change	43.03%	-16.42%	26.48%
Cash From Operating Activities	-$2.290M	-$3.309M	-$18.58M
YoY Change	-30.23%	-50.75%	-17.04%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$14.41K
YoY Change		-100.0%	-96.07%
Acquisitions
YoY Change
Other Investing Activities	-$1.000M
YoY Change
Cash From Investing Activities	-$1.000M	$0.00	-$14.41K
YoY Change		-100.0%	-94.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$11.06M
YoY Change			-35.85%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.292M	1.755M	15.92M
YoY Change	7.06%	2641.77%	-9.19%
NET CHANGE
Cash From Operating Activities	-2.290M	-3.309M	-18.58M
Cash From Investing Activities	-1.000M	0.000	-14.41K
Cash From Financing Activities	3.292M	1.755M	15.92M
Net Change In Cash	2.550K	-1.554M	-2.672M
YoY Change	-101.23%	-76.0%	-47.65%
FREE CASH FLOW
Cash From Operating Activities	-$2.290M	-$3.309M	-$18.58M
Capital Expenditures		$0.00	$14.41K
Free Cash Flow		-$3.309M	-$18.59M
YoY Change		-51.4%	-18.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Deferred Costs DeferredCosts		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39336
CY2023	dei	Entity Registrant Name EntityRegistrantName	Aditxt, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3204328
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	737 N. Fifth Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Richmond
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	23219
CY2023	dei	City Area Code CityAreaCode	(650)
CY2023	dei	Local Phone Number LocalPhoneNumber	870-1200
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	ADTX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	3008286	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1665214	shares
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	3501
CY2023	dei	Auditor Name AuditorName	dbbmckennon
CY2023	dei	Auditor Location AuditorLocation	San Diego, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97102	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2768640	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	745502	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	950093	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	217390	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	496869	usd
CY2023Q4	adtx	Subscription Receivable Current SubscriptionReceivableCurrent	5444628	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	6912948	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4743563	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1898243	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2318863	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9444	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	107000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	106410	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	355366	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2200299	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3160457	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	50000	usd
CY2023Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	22277211	usd
CY2023Q4	adtx	Acquisition Deposit AcquisitionDeposit	11173772	usd
CY2023Q4	us-gaap	Assets Assets	44578327	usd
CY2022Q4	us-gaap	Assets Assets	10735249	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8554959	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1958502	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	15653477	usd
CY2023Q4	adtx	Financing On Fixed Assets Current FinancingOnFixedAssetsCurrent	147823	usd
CY2022Q4	adtx	Financing On Fixed Assets Current FinancingOnFixedAssetsCurrent	409983	usd
CY2023Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	158612	usd
CY2022Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	188581	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	999943	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1086658	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25889814	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3643724	usd
CY2023Q4	adtx	Settlement Liability Noncurrent SettlementLiabilityNoncurrent	1600000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1041744	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1885218	usd
CY2023Q4	us-gaap	Liabilities Liabilities	28531558	usd
CY2022Q4	us-gaap	Liabilities Liabilities	5528942	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1318969	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107698	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1318918	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107647	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1319	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	108	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	51	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	51	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	201605	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	201605	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	143997710	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	100448166	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-127741072	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-95040362	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	16056377	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5206307	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-9608	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16046769	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5206307	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44578327	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10735249	usd
CY2023	us-gaap	Revenues Revenues	645176	usd
CY2022	us-gaap	Revenues Revenues	933715	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	756836	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	766779	usd
CY2023	us-gaap	Gross Profit GrossProfit	-111660	usd
CY2022	us-gaap	Gross Profit GrossProfit	166936	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18607142	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15985552	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7074339	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7268084	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	269284	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1849460	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	543938	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	25950765	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	25647034	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-26062425	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-25480098	usd
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	4195127	usd
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	753038	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	10166	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	57348	usd
CY2022	us-gaap	Other Income OtherIncome	58960	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2194773	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1533048	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	51712	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6328022	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2169778	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32390447	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27649876	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-32390447	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-27649876	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9608	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-32380839	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-27649876	usd
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	319871	usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	37667	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32700710	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27687553	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-108.15
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-597.12
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	302356	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46369	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5206307	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	609014	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	308479	usd
CY2023	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	507016	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	484525	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	10000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1581467	usd
CY2023	adtx	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1000	usd
CY2023	adtx	Stock Issued During Period Value Sale Of Series C Preferred Shares To Related Party StockIssuedDuringPeriodValueSaleOfSeriesCPreferredSharesToRelatedParty	-1000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	354838	usd
CY2023	adtx	Adjustments To Additional Paid In Capital Issuance Of Warrants For Offering Net Of Issuance Costs AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsForOfferingNetOfIssuanceCosts	14411028	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1000	usd
CY2023	adtx	Series A1 Preferred Shares Issued For Exchange Agreement SeriesA1PreferredSharesIssuedForExchangeAgreement	22277233	usd
CY2023	adtx	Stockissuedduringperiodvalue Note Exchange Agreement StockissuedduringperiodvalueNoteExchangeAgreement	2686309	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-32390447	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16046769	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10180773	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	1413904	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1209906	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	507558	usd
CY2022	adtx	Issuance Of Stock Exercise Of Warrants Modification Of Warrants And Issuance Of Warrants IssuanceOfStockExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants	1203769	usd
CY2022	adtx	Stock Issued During Period Value Sale Of Series B Preferred Shares To Related Party StockIssuedDuringPeriodValueSaleOfSeriesBPreferredSharesToRelatedParty	20000	usd
CY2022	adtx	Stock Issued During Period Value Redemption Of Series B Preferred Shares To Related Party StockIssuedDuringPeriodValueRedemptionOfSeriesBPreferredSharesToRelatedParty	20000	usd
CY2022	adtx	Shares Issued As Inducement On Loans Net Of Issuance Costs SharesIssuedAsInducementOnLoansNetOfIssuanceCosts	146522	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	878622	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	96030	usd
CY2022	adtx	Adjustments To Additional Paid In Capital Issuance Of Warrants For Offering Net Of Issuance Costs AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsForOfferingNetOfIssuanceCosts	17232307	usd
CY2022	adtx	Adjustments To Additional Paid In Issuance Costs Related To Exercise Of Warrants Modification Of Warrants And Issuance Of Warrants AdjustmentsToAdditionalPaidInIssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants	94195	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	80000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit	-13	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-27649876	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5206307	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-32390447	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-27649876	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1402018	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3131368	usd
CY2023	us-gaap	Depreciation Depreciation	435027	usd
CY2022	us-gaap	Depreciation Depreciation	428977	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	107556	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	107000	usd
CY2023	adtx	Amortization Of Debt Discount AmortizationOfDebtDiscount	2821629	usd
CY2022	adtx	Amortization Of Debt Discount AmortizationOfDebtDiscount	1533048	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	543938	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-6976	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	51712	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-119635	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	438117	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-279479	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	36767	usd
CY2023	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	-248956	usd
CY2022	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	-23884	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-204591	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	455396	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6646457	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	412959	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1600000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18576811	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22392006	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14407	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	367079	usd
CY2022	us-gaap	Proceeds From Sale Of Finance Receivables ProceedsFromSaleOfFinanceReceivables	125161	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14407	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-241918	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1062523	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	80000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	7903445	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2795000	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	687523	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	80000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3152488	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3206887	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11054883	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17233307	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1109574	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	262160	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	400491	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15919680	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17530503	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2671538	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5103421	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2768640	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7872061	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97102	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2768640	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2726020	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	753038	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	80000	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	878622	usd
CY2022	adtx	Debt Discount From Shares Issued As Inducement For Note Payable DebtDiscountFromSharesIssuedAsInducementForNotePayable	146522	usd
CY2023	adtx	Shares Issued For Debt Offering Costs SharesIssuedForDebtOfferingCosts	354838	usd
CY2022	adtx	Shares Issued For Debt Offering Costs SharesIssuedForDebtOfferingCosts	96030	usd
CY2023	adtx	Warrant Modification WarrantModification	319871	usd
CY2022	adtx	Warrant Modification WarrantModification	37677	usd
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	50000	usd
CY2023	adtx	Issuance Of Shares Of Pearsanta Common Stock For Ip IssuanceOfSharesOfPearsantaCommonStockForIP	10000	usd
CY2023	adtx	Assumption Of Notes Payable From Evofem Merger Agreement AssumptionOfNotesPayableFromEvofemMergerAgreement	11173750	usd
CY2023	adtx	Series A1 Preferred Shares Issued For Exchange Agreement SeriesA1PreferredSharesIssuedForExchangeAgreement	22277233	usd
CY2023	adtx	Accrued Intertest Rolled Into Notes Payable AccruedIntertestRolledIntoNotesPayable	701315	usd
CY2023	adtx	Series B2 Preferred Shares Issued In Note Exchange Agreement SeriesB2PreferredSharesIssuedInNoteExchangeAgreement	2686306	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Company Background</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a biotech innovation company with a mission of prolonging life and enhancing its quality by improving the health of the immune system. We are an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. Our immune reprogramming technologies are currently at the pre-clinical stage and are designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. Our immune monitoring technologies are designed to provide a personalized comprehensive profile of the immune system and we plan to utilize them in our upcoming reprogramming clinical trials to monitor subjects’ immune response before, during and after drug administration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 1, 2023, the Company formed Adimune, Inc., a Delaware wholly owned subsidiary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 1, 2023, the Company formed Pearsanta, Inc., a Delaware majority owned subsidiary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 13, 2023, the Company formed Adivir, Inc., a Delaware wholly owned subsidiary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 24, 2023, the Company formed Adivue, Inc., a Delaware wholly owned subsidiary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 16, 2023, the Company formed Adicure, Inc., a Delaware wholly owned subsidiary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse Stock Split</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 13, 2022, the Company effectuated a 1 for 50 reverse stock split (the “2022 Reverse Split”). The Company’s stock began trading on a split-adjusted basis effective on the Nasdaq Stock Market on September 14, 2022. There was no change to the number of authorized shares of the Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 17, 2023, the Company effectuated a 1 for 40 reverse stock split (the “2023 Reverse Split”). The Company’s stock began trading on a split-adjusted basis effective on the Nasdaq Stock Market on August 18, 2023. There was no change to the number of authorized shares of the Company’s common stock. All share amounts referenced in this report are adjusted to reflect the 2023 Reverse Split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Offerings</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 31, 2021, the Company completed a registered direct offering (“August 2021 Offering”). In connection therewith, the Company issued 2,292 shares of common stock, at a purchase price of $4,800.00 per share, resulting in gross proceeds of approximately $11.0 million. In a concurrent private placement, the Company issued warrants to purchase up to 2,292 shares. The warrants have an exercise price of $5,060.00 per share and are exercisable for a five-year period commencing months from the date of issuance. The warrants exercise price was subsequently repriced to $3,000.00. In addition, the Company issued a warrant to the placement agent to purchase up to 115 shares of common stock at an exercise price of $6,000.00 per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 18, 2021, the Company entered into an underwriting agreement with Revere Securities LLC, relating to the public offering (the “October 2021 Offering”) of 1,417 shares of the Company’s common stock (the “Shares”) by the Company. The Shares were offered, issued, and sold at a price to the public of $3,000.00 per share under a prospectus supplement and accompanying prospectus filed with the SEC pursuant to an effective shelf registration statement filed with the SEC on Form S-3 (File No. 333-257645), which was declared effective by the SEC on July 13, 2021. The October 2021 Offering closed on October 20, 2021 for gross proceeds of $4.25 million. The Company utilized a portion of the proceeds, net of underwriting discounts of approximately $3.91 million from the October 2021 Offering to fund certain obligations of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 6, 2021, the Company completed a public offering for net proceeds of $16.0 million (the “December 2021 Offering”). As part of the December 2021 Offering, we issued 4,123 units consisting of shares of the Company’s common stock and warrant to purchase shares of the Company’s common stock and 4,164 prefunded warrants. The warrant issued as part of the units had an exercise price of $2,300.00 and the prefunded warrants had an exercise price of $0.04. On June 15, 2022, the Company entered an agreement with a holder of certain warrants in the December 2021 Offering. (See Note 10)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 20, 2022, the Company completed a public offering for net proceeds of $17.2 million (the “September 2022 Offering”). As part of the September 2022 Offering, we issued 30,608 of shares of the Company’s common stock, pre-funded warrants to purchase 52,725 shares of common stock, and warrants to purchase 83,333 shares of the Company’s common stock. The warrants had an exercise price of $240.00 and the pre-funded warrants had an exercise price of $0.04.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 20, 2023, the Company entered into a securities purchase agreement (the “April Purchase Agreement”) with an institutional investor, pursuant to which the Company agreed to sell to such investor pre-funded warrants (the “April Pre-Funded Warrants”) to purchase up to 39,634 shares of common stock of the Company (the “Common Stock”) at a purchase price of $48.76 per April Pre-Funded Warrant. The April Pre-Funded Warrants (and shares of common stock underlying the April Pre-Funded Warrants) were offered by the Company pursuant to its shelf registration statement on Form S-3 (File No. 333-257645), which was declared effective by the Securities and Exchange Commission on July 13, 2021. Concurrently with the sale of the April Pre-Funded Warrants, pursuant to the Purchase Agreement in a concurrent private placement, for each April Pre-Funded Warrant purchased by the investor, such investor received from the Company an unregistered warrant (the “Warrant”) to purchase two shares of Common Stock. The warrants have an exercise price of $34.40 per share, and are exercisable for a three year period. In addition, the Company issued a warrant to the placement agent to purchase up to 2,378 shares of common stock at an exercise price of $61.00 per share. The closing of the sales of these securities under the April Purchase Agreement took place on April 24, 2023. The gross proceeds from the offering were approximately $1.9 million, prior to deducting placement agent’s fees and other offering expenses payable by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2023, the “Company entered into a securities purchase agreement (the “August Purchase Agreement”) with an institutional investor for the issuance and sale in a private placement (the “Private Placement”) of (i) pre-funded warrants (the “August Pre-Funded Warrants”) to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price of $0.001 per share, and (ii) warrants (the “Common Warrants”) to purchase up to 1,000,000 shares of the Company’s Common Stock at an exercise price of $10.00 per share. The Private Placement closed on September 6, 2023. The net proceeds to the Company from the Private Placement were approximately $9 million, after deducting placement agent fees and expenses and estimated offering expenses payable by the Company. The Company used the net proceeds received from the Private Placement for (i) the payment of approximately $3.1 million in outstanding obligations, (ii) the repayment of approximately $0.4 million of outstanding debt, and (iii) the balance for continuing operating expenses and working capital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 29, 2023, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (“the “Purchaser”) for the issuance and sale in a private placement (the “Private Placement”) of (i) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,237,114 shares of the Company’s common stock, par value $0.001 (the “Common Stock”) at an exercise price of $0.001 per share, and (ii) warrants (the “Common Warrants”) to purchase up to 2,474,228 shares of the Company’s Common Stock, at a purchase price of $4.85 per share. The Private Placement closed and the funds were received on January 4, 2024. The net proceeds to the Company from the Private Placement were approximately $5.4 million, after deducting placement agent fees and expenses and estimated offering expenses payable by the Company. The Company intends to use the net proceeds received from the Private Placement for continuing operating expenses and working capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks and Uncertainties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has a limited operating history and is in the very early stages of generating revenue from intended operations. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide along with local, state, and federal governmental policy decisions. A host of factors beyond the Company’s control could cause fluctuations in these conditions. Adverse conditions may include: changes in the biotechnology regulatory environment, technological advances that render our technologies obsolete, availability of resources for clinical trials, acceptance of technologies into the medical community, and competition from larger, more well-funded companies. These adverse conditions could affect the Company’s financial condition and the results of its operations.</span></p>
CY2022Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On September 13, 2022, the Company effectuated a 1 for 50 reverse stock split (the “2022 Reverse Split”)
CY2023Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On August 17, 2023, the Company effectuated a 1 for 40 reverse stock split (the “2023 Reverse Split”)
CY2021Q3	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	2292	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2292	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5060
CY2021Q3	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	3000
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	115	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1417	shares
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	3000
CY2021Q4	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	3910000	usd
CY2021Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	16000000	usd
CY2021Q4	adtx	Units Issued During Period Shares New Issues UnitsIssuedDuringPeriodSharesNewIssues	4123	shares
CY2021Q4	adtx	Prefunded Warrants Shares PrefundedWarrantsShares	4164	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2300
CY2021Q4	adtx	Prefunded Warrants Exercise Price PrefundedWarrantsExercisePrice	0.04
CY2022Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	17200000	usd
CY2022Q3	adtx	Purchase Of Equity Shares PurchaseOfEquityShares	52725	shares
CY2022Q3	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	83333	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	240
CY2022Q3	adtx	Prefunded Warrants Exercise Price PrefundedWarrantsExercisePrice	0.04
CY2023Q2	adtx	Purchase Of Common Stock Shares Issued PurchaseOfCommonStockSharesIssued	39634	shares
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9000000	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3100000	usd
CY2023Q3	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	400000	usd
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5400000
CY2023	us-gaap	Profit Loss ProfitLoss	-32390447	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18576811	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97102	usd
CY2023	us-gaap	Selling Expense SellingExpense	1800000	usd
CY2023Q2	adtx	Aggregate Market Value Of Voting And Nonvoting Equity AggregateMarketValueOfVotingAndNonvotingEquity	75000000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the financial statements include the collectability of notes receivable, the reserve on insurance billing, value of preferred shares issued, our investments in preferred shares, estimation of discounts on non-interest bearing borrowing, and the fair value of stock options and warrants.</p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentrations of Credit Risk</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially all the Company’s accounts receivable are with companies in the healthcare industry, individuals, and the U.S. government. However, concentration of credit risk is mitigated due to the Company’s number of customers. In addition, for receivables due from U.S. government agencies, the Company does not believe the receivables represent a credit risk as these are related to healthcare programs funded by the U.S. government and payment is primarily dependent upon submitting the appropriate documentation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	22711211	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	22711221	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	18634	usd
CY2023Q4	adtx	Accounts Receivable Billed AccountsReceivableBilled	236605	usd
CY2023Q4	adtx	Accounts Receivable Unbilled AccountsReceivableUnbilled	171721	usd
CY2022Q4	adtx	Accounts Receivable Billed AccountsReceivableBilled	527961	usd
CY2022Q4	adtx	Accounts Receivable Unbilled AccountsReceivableUnbilled	0	usd
CY2023	adtx	Licensing Fee For Patents LicensingFeeForPatents	123541	usd
CY2022	adtx	Licensing Fee For Patents LicensingFeeForPatents	263273	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	7074339	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	7268084	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-9608	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3149258	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1251015	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1898243	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3134850	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	815987	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2318863	usd
CY2023	us-gaap	Depreciation Depreciation	435027	usd
CY2022	us-gaap	Depreciation Depreciation	428977	usd
CY2023Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1316830	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1359091	usd
CY2020Q4	us-gaap	Equipment Expense EquipmentExpense	19487	usd
CY2021Q1	us-gaap	Equipment Expense EquipmentExpense	9733	usd
CY2021Q1	us-gaap	Equipment Expense EquipmentExpense	37171	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	321000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	321556	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9444	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	321000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	214000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	107000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	107556	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	107000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P3Y
CY2022Q1	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	9600	shares
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	146613	usd
CY2022Q1	adtx	Number Of Shares Issued NumberOfSharesIssued	1	shares
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	20000	usd
CY2022Q3	us-gaap	Loans Receivable With Fixed Rates Of Interest1 LoansReceivableWithFixedRatesOfInterest1	80000	usd
CY2022Q4	adtx	Promissory Notes PromissoryNotes	80000	usd
CY2023Q3	adtx	Number Of Shares Issued NumberOfSharesIssued	1	shares
CY2023Q4	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	10000	usd
CY2023Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	10000	usd
CY2023Q4	us-gaap	Financing Receivable Excluding Accrued Interest Revolving Converted To Term Loan FinancingReceivableExcludingAccruedInterestRevolvingConvertedToTermLoan	72	usd
CY2023Q4	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	200000	usd
CY2023Q4	us-gaap	Financing Receivable Excluding Accrued Interest Revolving Converted To Term Loan FinancingReceivableExcludingAccruedInterestRevolvingConvertedToTermLoan	423	usd
CY2023Q1	adtx	Gross Proceeds GrossProceeds	1500000	usd
CY2023Q1	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	75000	usd
CY2023Q3	us-gaap	Debt Instrument Repurchased Face Amount DebtInstrumentRepurchasedFaceAmount	77000	usd
CY2023Q2	us-gaap	Proceeds From Loans ProceedsFromLoans	2000000	usd
CY2023Q2	adtx	Future Receipts Agreement FutureReceiptsAgreement	1157143	usd
CY2023Q2	adtx	Net Proceeds NetProceeds	742857	usd
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1060000	usd
CY2023Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	60000	usd
CY2023Q2	adtx	Net Proceeds NetProceeds	860500	usd
CY2023Q2	us-gaap	Loans Payable LoansPayable	1060000	usd
CY2023Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	60000	usd
CY2023Q2	adtx	Total Amount Of Interest And Fees Payable TotalAmountOfInterestAndFeesPayable	1590000	usd
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2000000	usd
CY2023Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	100000	usd
CY2023Q2	adtx	Total Amount Of Interest And Fees Payable TotalAmountOfInterestAndFeesPayable	2880000	usd
CY2023Q3	adtx	Principal Amount PrincipalAmount	215000	usd
CY2023Q3	us-gaap	Legal Fees LegalFees	10750	usd
CY2023	adtx	Business Loan And Security Agreement BusinessLoanAndSecurityAgreement	The total amount of interest and fees payable by the Company to the Lender under the Loan (the “July Repayment Amount”) will be (i) $322,285 and will be repaid in 13 weekly installments of $24,500 with a final payment of $3,785 in the fourteenth week. As of December 31, 2023, the note was fully paid off.
CY2023Q3	us-gaap	Loans Payable LoansPayable	1400000	usd
CY2023Q3	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	70000	usd
CY2023Q3	adtx	Total Amount Of Interest And Fees Payable TotalAmountOfInterestAndFeesPayable	2079000	usd
CY2023Q4	us-gaap	Sale Leaseback Transaction Gross Proceeds Financing Activities SaleLeasebackTransactionGrossProceedsFinancingActivities	4470000	usd
CY2023Q4	adtx	Gross Proceeds GrossProceeds	3000000	usd
CY2023Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	240000	usd
CY2023Q4	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	1234461	usd
CY2023Q4	adtx	Net Proceeds NetProceeds	1525539	usd
CY2023Q4	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	3870000	usd
CY2023Q4	us-gaap	Repayments Of Assumed Debt RepaymentsOfAssumedDebt	4230000	usd
CY2023Q4	us-gaap	Repayments Of Assumed Debt RepaymentsOfAssumedDebt	3129000	usd
CY2023Q4	adtx	Principal Amount PrincipalAmount	53099	usd
CY2023Q4	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.085	pure
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	458	usd
CY2023Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	164775	usd
CY2023Q3	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	18
CY2023Q3	us-gaap	Capital Units Total Cost To Investors CapitalUnitsTotalCostToInvestors	10066	usd
CY2023Q4	us-gaap	Secured Debt SecuredDebt	5000000	usd
CY2023Q3	us-gaap	Gain Loss On Sales Of Loans Net GainLossOnSalesOfLoansNet	154480	usd
CY2023	adtx	Principal Amount PrincipalAmount	13000000	usd
CY2023	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	610000	shares
CY2023	adtx	Warrrants To Exchange Shares WarrrantsToExchangeShares	551	shares
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	1140949	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	1396875	usd
CY2023	us-gaap	Lease Cost LeaseCost	1140949	usd
CY2022	us-gaap	Lease Cost LeaseCost	1396875	usd
CY2023Q4	adtx	Right Of Use Asset Long Term RightOfUseAssetLongTerm	2200299	usd
CY2022Q4	adtx	Right Of Use Asset Long Term RightOfUseAssetLongTerm	3160457	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2200299	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	3160457	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	999943	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1086658	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1041744	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1885218	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2041687	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2971876	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y11M1D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1004982	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	710546	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	423930	usd
CY2023Q4	adtx	Lessee Operating Lease Liability Payment Due LesseeOperatingLeaseLiabilityPaymentDue	2139458	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	97771	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	999943	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1041744	usd
CY2023Q4	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	13	shares
CY2020Q3	us-gaap	Taxes And Licenses TaxesAndLicenses	455000	usd
CY2022Q1	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	175000	usd
CY2023Q1	us-gaap	Other Payments To Acquire Businesses OtherPaymentsToAcquireBusinesses	175000	usd
CY2023Q1	srt	Extensions Discoveries Additions And Improved Recovery Less Related Costs ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts	100000	usd
CY2018	us-gaap	Information Technology And Data Processing InformationTechnologyAndDataProcessing	70000	usd
CY2019Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	60000	usd
CY2023	us-gaap	Product Liability Contingency Third Party Recovery Percentage ProductLiabilityContingencyThirdPartyRecoveryPercentage	0.0075	pure
CY2023	adtx	Expiration Period ExpirationPeriod	P3Y
CY2023	srt	Extensions Discoveries Additions And Improved Recovery Less Related Costs ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts	100000	usd
CY2023	us-gaap	Investment Company Fee Paid Indirectly InvestmentCompanyFeePaidIndirectly	25000	usd
CY2023	us-gaap	Sale Leaseback Transaction Other Payments Required SaleLeasebackTransactionOtherPaymentsRequired	25000	usd
CY2023	adtx	Payment Of Milestone Fees PaymentOfMilestoneFees	50000	usd
CY2023	us-gaap	Clearance Fees ClearanceFees	25000	usd
CY2022Q1	us-gaap	Registration Payment Arrangement Maximum Potential Consideration RegistrationPaymentArrangementMaximumPotentialConsideration	25000	usd
CY2020Q2	us-gaap	Financial Guarantee Insurance Contracts Accelerated Premium Revenue Amount FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount	10000000	usd
CY2023	us-gaap	Broadcasters License Agreement Commitments Description BroadcastersLicenseAgreementCommitmentsDescription	In addition to the annual license maintenance fees outlined above, we will pay Stanford royalties on Net Sales (as such term is defined in the February 2020 License Agreement) during the of the term of the agreement as follows: 4% when Net Sales are below or equal to $5 million annually or 6% when Net Sales are above $5 million annually.
CY2023Q2	adtx	Asset Purchase Agreement AssetPurchaseAgreement	24500000	usd
CY2023Q2	us-gaap	Loans Payable LoansPayable	14500000	usd
CY2023Q2	adtx	Payments Term PaymentsTerm	P7Y
CY2023Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	122292	usd
CY2023Q3	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	32576	usd
CY2023Q3	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	2000000	usd
CY2023	adtx	Common Stock Outstanding Owned Percentage CommonStockOutstandingOwnedPercentage	0.0999	pure
CY2023Q4	adtx	Black Scholes Valuation Model BlackScholesValuationModel	470772	usd
CY2023Q3	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	1600000	usd
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On September 13, 2022, the Company effectuated a 1 for 50 reverse stock split (the “2022 Reverse Split”).
CY2023	us-gaap	Stock Issued During Period Shares Share Based Compensation Gross StockIssuedDuringPeriodSharesShareBasedCompensationGross	74675	shares
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	484525	usd
CY2023	adtx	Common Stock For The Exercise Of Warrants CommonStockForTheExerciseOfWarrants	1055374	shares
CY2022Q4	adtx	Aggregate Shares Price AggregateSharesPrice	50000000	usd
CY2023	us-gaap	Insurance Commissions And Fees InsuranceCommissionsAndFees	507016	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023	adtx	Series A1 Preferred Stock Designated Shares SeriesA1PreferredStockDesignatedShares	22280	shares
CY2023	adtx	Conversion Price ConversionPrice	4.44
CY2023	adtx	Excess Of Beneficially Owned Percentage ExcessOfBeneficiallyOwnedPercentage	0.0499	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	5.01
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0449	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.64	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	127281	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	514.97
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y6M14D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5975936	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.92
CY2023	adtx	Weighted Average Remaining Life Granted WeightedAverageRemainingLifeGranted	P2Y8M19D
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1055374	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.24
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	393	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8249.36
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5047450	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.11
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y8M23D
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	9086	shares
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	6128	usd
CY2023Q2	adtx	Exercisable Period ExercisablePeriod	P3Y
CY2023Q2	adtx	Black Scholes Valuation Model BlackScholesValuationModel	56742	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	60000	shares
CY2023Q3	adtx	Warrants Issued Black Scholes Valuation WarrantsIssuedBlackScholesValuation	1900000	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9000000	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3100000	usd
CY2023Q3	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	400000	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	5444628	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1843902	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.008	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.016	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.005	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.01	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.019	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.105	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.205	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.131	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18555428	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13499811	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	796320	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	430468	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1580038	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1511849	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Gain On Sale Leaseback Transaction DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction	486473	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Gain On Sale Leaseback Transaction DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction	722126	usd
CY2023Q4	adtx	Deferred Tax Assets Section174 Capitalization DeferredTaxAssetsSection174Capitalization	2207611	usd
CY2022Q4	adtx	Deferred Tax Assets Section174 Capitalization DeferredTaxAssetsSection174Capitalization	1547343	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	3326129	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	3288363	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	92704	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	114973	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	27044703	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21114933	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26414533	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	20217400	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	630170	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	897533	usd
CY2023Q4	adtx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	486473	usd
CY2022Q4	adtx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	722127	usd
CY2023Q4	adtx	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	143697	usd
CY2022Q4	adtx	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	175406	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	630170	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	897533	usd
CY2023Q4	us-gaap	Tax Credit Carryforward Valuation Allowance TaxCreditCarryforwardValuationAllowance	6200000	usd
CY2022Q4	us-gaap	Tax Credit Carryforward Valuation Allowance TaxCreditCarryforwardValuationAllowance	3500000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	75200000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	56600000	usd
CY2023	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	The CARES Act temporarily allows the Company to carryback net operating losses arising in 2018, 2019 and 2020 to the five prior tax years
CY2017Q4	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.80	pure
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	28200000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	26200000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	100000	usd
CY2022Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	0.1	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	400000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	200000	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	5500000	usd
CY2023Q4	us-gaap	Shares Issued SharesIssued	74227	shares
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	6.0625
CY2023Q4	us-gaap	Secured Debt SecuredDebt	5200000	usd
CY2023	adtx	Third Amendment To The Merger Agreement Description ThirdAmendmentToTheMergerAgreementDescription	On February 29, 2024, the Company, Adicure and Evofem entered into the Third Amendment to the Merger Agreement (the “Third Amendment to Merger Agreement”) in order to (i) make certain conforming changes to the Merger Agreement regarding the Notes, (ii) extend the date by which the Company and Evofem will file the joint proxy statement until April 30, 2024, and (iii) remove the requirement that the Company make the Parent Loan (as defined in the Merger Agreement) by February 29, 2024 and replace it with the requirement that the Company make an equity investment into Evofem consisting of (a) a purchase of 2,000 shares of Evofem Series F-1 Preferred Stock for an aggregate purchase price of $2.0 million on or prior to April 1, 2024, and (b) a purchase of 1,500 shares of Evofem Series F-1 Preferred Stock for an aggregate purchase price of $1.5 million on or prior to April 30, 2024. As of the date of this filing the Company has not purchased the 2,000 shares of EvoFem Series F-1 Preferred Stock.
CY2023	adtx	Dawson Engagement Letter Description DawsonEngagementLetterDescription	the Company agreed to pay Dawson an initial fee of $1.85 million (the “Dawson Initial Fee”), which amount is payable on the later of (i) the closing of an offering resulting in gross proceeds to the Company of greater than $4.9 million, or (ii) five days after the execution of the Dawson Engagement Letter. At the Company’s option, the Dawson Initial Fee may be paid in securities of the Company. In addition, with respect to any business combination (i) that either is introduced to the Company by Dawson following the date of the Dawson Engagement Letter or (ii) that with respect to which the Company hereafter requests Dawson to provide M&A advisory services, the Company shall compensate Dawson in an amount equal to 5% of the Total Transaction Value (as defined in the Engagement Letter) with respect to the first $20.0 million in Total Transaction Value plus 10.0% of the Total Transaction Value that is in excess of $20.0 million (the “Transaction Fee”)
CY2023	adtx	Appili Arrangement Agreement Consideration Description AppiliArrangementAgreementConsiderationDescription	(i) $0.0467 in cash consideration per share for an aggregate cash payment of $5,668,222 (the “Cash Consideration”) and (ii) 0.002745004 of a share of common stock of Aditxt or an aggregate of 332,876 shares (the “Consideration Shares” and together with the Cash Consideration, the “Transaction Consideration”). In connection with the transaction, each outstanding option and warrant of Appili will be cashed-out based on the implied in-the-money value of the Transaction Consideration, which is expected to result in an additional aggregate cash payment of approximately $341,000 (based on the number of issued and outstanding options and warrants and exchange rates as of the date of the Arrangement Agreement)
CY2022Q4	adtx	Acquisition Deposit AcquisitionDeposit		usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2022Q4	adtx	Settlement Liability Noncurrent SettlementLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest		usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2023	us-gaap	Other Income OtherIncome		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-108.15
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-595.60
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	302356	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46369	shares
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation		usd
CY2023	adtx	Adjustments To Additional Paid In Capital Modification Of Warrants In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalModificationOfWarrantsInExcessOfRetainedEarnings		usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit		usd
CY2022	adtx	Adjustments To Additional Paid In Capital Modification Of Warrants In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalModificationOfWarrantsInExcessOfRetainedEarnings		usd
CY2022	adtx	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised		usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		usd
CY2023	us-gaap	Proceeds From Sale Of Finance Receivables ProceedsFromSaleOfFinanceReceivables		usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	us-gaap	Stock Issued1 StockIssued1		usd
CY2023	adtx	Debt Discount From Shares Issued As Inducement For Note Payable DebtDiscountFromSharesIssuedAsInducementForNotePayable		usd
CY2023	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction		usd
CY2022	adtx	Issuance Of Shares Of Pearsanta Common Stock For Ip IssuanceOfSharesOfPearsantaCommonStockForIP		usd
CY2022	adtx	Assumption Of Notes Payable From Evofem Merger Agreement AssumptionOfNotesPayableFromEvofemMergerAgreement		usd
CY2022	adtx	Series A1 Preferred Shares Issued For Exchange Agreement SeriesA1PreferredSharesIssuedForExchangeAgreement		usd
CY2022	adtx	Accrued Intertest Rolled Into Notes Payable AccruedIntertestRolledIntoNotesPayable		usd
CY2022	adtx	Series B2 Preferred Shares Issued In Note Exchange Agreement SeriesB2PreferredSharesIssuedInNoteExchangeAgreement		usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments		usd
CY2023	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments		usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent		usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest		usd
CY2023	adtx	Weighted Average Remaining Life Exercised WeightedAverageRemainingLifeExercised
CY2023	adtx	Weighted Average Remaining Life Expired Or Forfeited WeightedAverageRemainingLifeExpiredOrForfeited
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001726711

Files In Submission

Name	View Source	Status
0001213900-24-033466-index-headers.html	Edgar Link	pending
0001213900-24-033466-index.html	Edgar Link	pending
0001213900-24-033466.txt	Edgar Link	pending
0001213900-24-033466-xbrl.zip	Edgar Link	pending
adtx-20231231.xsd	Edgar Link	pending
ea0203762-10k_aditxt.htm	Edgar Link	pending
ea020376201ex23-1_aditxt.htm	Edgar Link	pending
ea020376201ex31-1_aditxt.htm	Edgar Link	pending
ea020376201ex31-2_aditxt.htm	Edgar Link	pending
ea020376201ex32-1_aditxt.htm	Edgar Link	pending
ea020376201ex97-1_aditxt.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
adtx-20231231_def.xml	Edgar Link	unprocessable
adtx-20231231_lab.xml	Edgar Link	unprocessable
adtx-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0203762-10k_aditxt_htm.xml	Edgar Link	completed
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
adtx-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADTX
Aditxt, Inc. Stock $adtx

2024 Q2 Form 10-K Financial Statement

#000121390024033466 Filed on April 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADTX Aditxt, Inc. Stock $adtx

2024 Q2 Form 10-K Financial Statement

#000121390024033466 Filed on April 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADTX
Aditxt, Inc. Stock $adtx